ADVERTISEMENT
Avelumab-Based Neoadjuvant Chemotherapy for Patients With Non–Metastatic, Muscle-Invasive Bladder Cancer: AURA Trial
Nieves Martínez Chanzá, MD, PhD, Jules Bordet Institute, Belgium, discusses avelumab as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients with non-metastatic muscle invasive bladder cancer, presented at the 2021 ESMO Congress.
Disclaimer: The views and opinions expressed are those of the author(s) and do not necessarily reflect the official policy or position of Oncology Learning Network or HMP Global, their employees, and affiliates. Any content provided by our bloggers or authors are of their opinion and are not intended to malign any religion, ethnic group, club, association, organization, company, individual, anyone, or anything.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement